MARKET

RANI

RANI

Rani Therapeutics Holdings, Inc.
NASDAQ
1.110
+0.060
+5.71%
After Hours: 1.110 0 0.00% 16:08 05/14 EDT
OPEN
1.060
PREV CLOSE
1.050
HIGH
1.140
LOW
1.045
VOLUME
1.57M
TURNOVER
--
52 WEEK HIGH
3.870
52 WEEK LOW
0.3870
MARKET CAP
137.40M
P/E (TTM)
-2.4738
1D
5D
1M
3M
1Y
5Y
1D
Rani Therapeutics joins H.C. Wainwright BioConnect investor conference at Nasdaq
PUBT · 2d ago
Weekly Report: what happened at RANI last week (0504-0508)?
Weekly Report · 3d ago
Edward Nash Reiterates Buy on Rani Therapeutics, Maintains Unchanged $5 Price Target Amid Encouraging RT-114 and Oral Biologics Platform Outlook
TipRanks · 05/07 13:57
Weekly Report: what happened at RANI last week (0427-0501)?
Weekly Report · 05/04 10:37
Weekly Report: what happened at RANI last week (0420-0424)?
Weekly Report · 04/27 10:41
Weekly Report: what happened at RANI last week (0413-0417)?
Weekly Report · 04/20 10:36
Weekly Report: what happened at RANI last week (0406-0410)?
Weekly Report · 04/13 10:41
Rani Therapeutics names Sara Kenkare-Mitra strategic advisor on platform, clinical strategy
Reuters · 04/09 11:03
More
About RANI
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).

Webull offers Rani Therapeutics Holdings Inc stock information, including NASDAQ: RANI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RANI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RANI stock methods without spending real money on the virtual paper trading platform.